IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
MWN-AI** Summary
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has announced that it has enrolled the first patient in a Phase 1/2 clinical trial investigating IDE397, a potential first-in-class MAT2A inhibitor, in combination with Trodelvy® (sacituzumab govitecan-hziy), for the treatment of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletions. This announcement comes as part of an ongoing clinical collaboration between IDEAYA and Gilead Sciences, which initially focused on MTAP-deleted urothelial cancer but has now expanded to include NSCLC.
MTAP-deletions occur in approximately 20% of NSCLC cases and represent a significant area of unmet medical need, as there are currently no approved targeted therapies for this patient population. IDEAYA's Chief Medical Officer, Darrin Beaupre, expressed optimism about the combination therapy, highlighting encouraging preliminary data from earlier trials in bladder cancer and emphasizing the importance of exploring this combination across multiple solid tumors.
Trodelvy, an antibody-drug conjugate, is already approved for other indications, including metastatic triple-negative breast cancer and certain cases of HR+/HER2- metastatic breast cancer. However, its application in MTAP-deletion NSCLC and urothelial carcinoma remains investigational, and the efficacy and safety of the combination of IDE397 and Trodelvy have not been fully established.
The collaboration agreement allows both IDEAYA and Gilead to retain commercial rights to their respective compounds, working together to advance this promising treatment approach. IDEAYA aims to leverage its strengths in precision medicine and oncology to develop targeted therapies aligned with the genetic drivers of cancers while acknowledging the risks associated with the drug development process.
MWN-AI** Analysis
IDEAYA Biosciences' recent announcement regarding the initiation of a Phase 1/2 combination trial for IDE397 and Trodelvy® in MTAP-deletion non-small cell lung cancer (NSCLC) presents a pivotal opportunity for investors in the biotech sector. This trial marks a significant step in exploring a novel therapeutic avenue; online reports indicate that MTAP-deletion occurs in 20% of NSCLC cases, underscoring a substantial unmet need in this patient population.
From a market perspective, IDEAYA's strategic collaboration with Gilead Sciences can enhance credibility and resource availability, especially given Gilead's established portfolio with Trodelvy. Investors should value IDEAYA not only for its innovative approach but also for its growing pipeline, which is rooted in precision oncology. The dual focus on synthetic lethality and antibody-drug conjugates positions the company at the forefront of evolving cancer therapies.
However, investors should exercise caution. While the trial initiation is a positive development, it is essential to remember that IDE397 and its combination with Trodelvy have not yet received regulatory approval, leaving the efficacy and safety of this new regimen unverified. Regulatory timelines can be unpredictable, and the drug development process is fraught with risks that could hinder progress or delay potential commercialization.
As the clinical landscape evolves, it will be important for investors to monitor upcoming data releases and trial results closely, particularly concerning safety profiles and efficacy in MTAP-deleted tumors. Market sentiment could be substantially influenced by any positive data or regulatory advancements, as successful trials can lead to stock appreciation.
Considering the high-risk, high-reward nature of biotechnology investments, those interested in IDEAYA should conduct thorough due diligence, maintain a diversified portfolio to mitigate risks, and remain engaged with the company's ongoing developments to maximize potential returns.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SOUTH SAN FRANCISCO, Calif. , Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2a) inhibitor, and Trodelvy ® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with methylthioadenosine phosphorylase (MTAP)-deletion solid tumors. IDEAYA is conducting the trial pursuant to a clinical study collaboration and supply agreement with Gilead, where the initial focus was in MTAP-deletion urothelial cancer (UC). In April 2025 , the companies announced expansion of the combination trial into MTAP-deletion NSCLC.
"We are encouraged by the preliminary expansion data from our Phase 1/2 combination trial with IDE397 and Trodelvy in MTAP-deleted bladder cancer and excited to have dosed the first patient in the non-small cell lung cancer cohort. This marks an important step in our broader clinical strategy to evaluate the combination across multiple solid tumors with MTAP-deletion," said Darrin Beaupre , Chief Medical Officer, IDEAYA Biosciences.
"MTAP-deletion is found in up to 20% of non-small cell lung cancer and remains an area with no approved targeted therapies. We're pleased to expand our collaboration with IDEAYA and explore the potential of this novel combination in a patient population with limited treatment options," said Bilal Piperdi , MD, Vice President, Clinical Development Oncology at Gilead Sciences.
Pursuant to the clinical study collaboration and supply agreement, IDEAYA and Gilead retain the commercial rights to their respective compounds, including with respect to use as a monotherapy or combination agent. IDEAYA is the study sponsor, and Gilead will provide the supply of Trodelvy to IDEAYA.
Trodelvy is currently approved in more than 50 countries for second-line or later metastatic triple-negative breast cancer (TNBC) patients and in more than 40 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.
The use of Trodelvy in MTAP-deletion NSCLC and UC is investigational, and the safety and efficacy of this use have not been established. IDE397 monotherapy or in combination with Trodelvy has not been approved by any regulatory agency and the efficacy and safety of this combination has not been established.
Trodelvy and Gilead are trademarks of Gilead Sciences, Inc., or its related companies.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential therapeutic benefits of IDE397and Trodelvy combination. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski , Ph.D.
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
FAQ**
What are the primary endpoints of the Phase 1/2 trial evaluating IDE397 and Trodelvy in MTAP-deletion non-small cell lung cancer, as mentioned by IDEAYA Biosciences Inc. IDYA?
How does IDEAYA Biosciences Inc. IDYA plan to leverage preliminary data from the combination trial to potentially expand its pipeline for other cancer types?
What are the anticipated challenges IDEAYA Biosciences Inc. IDYA may face regarding regulatory approval for the combination of IDE397 and Trodelvy in MTAP-deletion NSCLC?
How does the partnership between IDEAYA Biosciences Inc. IDYA and Gilead enhance the clinical development of therapies targeting MTAP-deletion solid tumors?
**MWN-AI FAQ is based on asking OpenAI questions about IDEAYA Biosciences Inc. (NASDAQ: IDYA).
NASDAQ: IDYA
IDYA Trading
-1.52% G/L:
$32.48 Last:
170,945 Volume:
$33.22 Open:
